OVARIAN EPITHELIAL, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCERS TREATMENT

Abstract

There are several other forms of ovarian cancer, but the most common type that occurs in about 90% of all cases is epithelial ovarian cancer. Though less common, sexual colt electrotumors and germ cell tumors are other subtypes that face specific therapeutic challenges. Hormonal, ecological, and genetic effects combine with complex interactions in the pathophysiology of ovarian cancer. The risk of ovarian cancer associated with larger genetic defects, such as the BRCA1 and BRCA2 genes, was increased. Mutations are particularly important for women with a family history of the disease. Some of the signs of ovarian cancer are flatulence, abdominal or pelvic pain, urgency in the urine, and changes in intestinal habits that are usually not specific. However, symptoms are often misinterpreted in benign diseases, resulting in slow diagnosis. If the disease spreads to other areas of the abdomen or even more, more than 70% of cases of stage III or IV ovarian cancer are diagnosed. Early detection remains extremely difficult as there are no proven screening tests for ovarian cancer at this point. Chemotherapy and surgery are the most common treatments for ovarian cancer. The most important treatment in the treatment of advanced ovarian cancer is surgical weight loss, which attempts to remove as much tumor tissue as possible. Immunotherapy and target active ingredients have become increasingly important in recent years. Olaparib and other PARP inhibitors were also promising in patients with BRCA Gen mutations, offering a new strategy by using cancer cell debilitating for DNA repair. Research on electrocellular and extracellular matrix to promote cancer growth and metastasis is also increasing in the current body of knowledge about ovarian cancer.